Jan K DamÃ¥s

List of Publications by Year
in descending order

148 papers	7,705 citations	50276 46 h-index	60623 81 g-index
154 all docs	154 docs citations	154 times ranked	12614 citing authors

#	Article	IF	Citations
1	Risk of lower respiratory tract infections: a genome-wide association study with Mendelian randomization analysis in three independent European populations. Clinical Microbiology and Infection, 2022, 28, 732.e1-732.e7.	6.0	2
2	The inflammatory response is related to circulatory failure after out-of-hospital cardiac arrest: A prospective cohort study. Resuscitation, 2022, 170, 115-125.	3.0	19
3	Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine, 2022, 80, 104013.	6.1	22
4	Explaining sex differences in risk of bloodstream infections using mediation analysis in the population-based HUNT study in Norway. Scientific Reports, 2022, 12, 8436.	3.3	10
5	Inflammatory Markers and Radiotherapy Response in Patients With Painful Bone Metastases. Journal of Pain and Symptom Management, 2022, 64, 330-339.	1.2	1
6	The Role of FER rs4957796 in the Risk of Developing and Dying from a Bloodstream Infection: A 23-Year Follow-up of the Population-based Nord-TrÃ¸ndelag Health Study. Clinical Infectious Diseases, 2021, 73, e297-e303.	5.8	1
7	Secreted Wnt antagonists in scrub typhus. PLoS Neglected Tropical Diseases, 2021, 15, e0009185.	3.0	3
8	Randomized Trial of Interleukin-6 Receptor Inhibition in Patients WithÂAcute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 1845-1855.	2.8	169
9	Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway. BMC Infectious Diseases, 2021, 21, 659.	2.9	18
10	GWAS Identifies LINC01184/SLC12A2 as a Risk Locus for Skin and Soft Tissue Infections. Journal of Investigative Dermatology, 2021, 141, 2083-2086.e8.	0.7	4
11	Hepatitis C outreach project and cross-sectional epidemiology in high-risk populations in Trondheim, Norway. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110539.	1.8	3
12	Thyroid function and risk of bloodstream infections: Results from the Norwegian prospective populationâ€based HUNT Study. Clinical Endocrinology, 2021, , .	2.4	2
13	Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. Nature Communications, 2020, 11, 147.	12.8	62
14	Genome-Wide Linkage Analysis of the Risk of Contracting a Bloodstream Infection in 47 Pedigrees Followed for 23 Years Assembled From a Population-Based Cohort (the HUNT Study)*. Critical Care Medicine, 2020, 48, 1580-1586.	0.9	3
15	Cardiometabolic Traits, Sepsis, and Severe COVID-19. Circulation, 2020, 142, 1791-1793.	1.6	93
16	Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. EBioMedicine, 2020, 60, 102985.	6.1	41
17	Novel Insights Into the Effects of Interleukin 6 Antagonism in Nonâ€“STâ€Segmentâ€“Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform. Journal of the American Heart Association, 2020, 9, e015628.	3.7	16
18	TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria. Journal of Leukocyte Biology, 2020, 107, 673-683.	3.3	9

#	Article	IF	Citations
19	Systemic Inflammation Persists the First Year after Mild Traumatic Brain Injury: Results from the Prospective Trondheim Mild Traumatic Brain Injury Study. Journal of Neurotrauma, 2020, 37, 2120-2130.	3.4	49
20	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. PLoS Medicine, 2020, 17, e1003413.	8.4	15
21	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
22	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
23	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
24	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
25	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
26	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
27	Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. International Journal of Cardiology, 2019, 274, 348-350.	1.7	11
28	Monitoring quality of care for peripheral intravenous catheters; feasibility and reliability of the peripheral intravenous catheters mini questionnaire (PIVC-miniQ). BMC Health Services Research, 2019, 19, 636.	2.2	19
29	Human Toll-like Receptor 8 (TLR8) Is an Important Sensor of Pyogenic Bacteria, and Is Attenuated by Cell Surface TLR Signaling. Frontiers in Immunology, 2019, 10, 1209.	4.8	49
30	Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Open Heart, 2019, 6, e001108.	2.3	34
31	Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. Circulation Genomic and Precision Medicine, 2019, 12, e002335.	3.6	11
32	Transcapillary fluid flux and inflammatory response during neonatal therapeutic hypothermia: an open, longitudinal, observational study. BMC Pediatrics, 2018, 18, 82.	1.7	1
33	Anxiety and Depression Symptoms in a General Population and Future Risk of Bloodstream Infection: The HUNT Study. Psychosomatic Medicine, 2018, 80, 673-679.	2.0	18
34	Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. Open Heart, 2018, 5, e000765.	2.3	15
35	IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction. Frontiers in Immunology, 2018, 9, 2035.	4.8	21
36	The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain. BMC Palliative Care, 2018, 17, 110.	1.8	10

#	Article	IF	Citations
37	Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1Î² in non-ST-elevation myocardial infarction. International Journal of Cardiology, 2018, 271, 1-7.	1.7	22
38	Association of iron status with the risk of bloodstream infections: results from the prospective population-based HUNT Study in Norway. Intensive Care Medicine, 2018, 44, 1276-1283.	8.2	27
39	Expression of neutrophil gelatinase-associated lipocalin (NGAL) in the gut in Crohnâ€™s disease. Cell and Tissue Research, 2018, 374, 339-348.	2.9	25
40	Transitions Between Circulatory States After Out-of-Hospital Cardiac Arrest: Protocol for an Observational, Prospective Cohort Study. JMIR Research Protocols, 2018, 7, e17.	1.0	6
41	Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study. BMC Infectious Diseases, 2017, 17, 116.	2.9	25
42	Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart, 2017, 103, 1521-1527.	2.9	46
43	Extracellular matrix markers and risk of myocardial infarction: The HUNT Study in Norway. European Journal of Preventive Cardiology, 2017, 24, 1161-1167.	1.8	13
44	Monocyte/macrophage and T cell activation markers are not independently associated with MI risk in healthy individuals - results from the HUNT Study. International Journal of Cardiology, 2017, 243, 502-504.	1.7	4
45	Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study. BMC Infectious Diseases, 2017, 17, 205.	2.9	56
46	N-3 PUFAs induce inflammatory tolerance by formation of KEAP1-containing SQSTM1/p62-bodies and activation of NFE2L2. Autophagy, 2017, 13, 1664-1678.	9.1	43
47	Cyclodextrin Reduces Cholesterol Crystalâ€“Induced Inflammation by Modulating Complement Activation. Journal of Immunology, 2017, 199, 2910-2920.	0.8	31
48	Cyclodextrin inhibits CC-induced complement activation. Molecular Immunology, 2017, 89, 167-168.	2.2	0
49	Associations of obesity and lifestyle with the risk and mortality of bloodstream infection in a general population: a 15-year follow-up of 64â€‰027 individuals in the HUNT Study. International Journal of Epidemiology, 2017, 46, 1573-1581.	1.9	48
50	Fecal neutrophil gelatinaseâ€associated lipocalin as a biomarker for inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 128-135.	2.8	66
51	Bronchial microdialysis monitoring of inflammatory response in open abdominal aortic aneurysm repair; an observational study. Physiological Reports, 2017, 5, e13348.	1.7	4
52	Toll-Like Receptor 8 Is a Major Sensor of Group B Streptococcus But Not Escherichia coli in Human Primary Monocytes and Macrophages. Frontiers in Immunology, 2017, 8, 1243.	4.8	29
53	Epidemiology and outcome of sepsis in adult patients with Streptococcus pneumoniae infection in a Norwegian county 1993â€“2011: an observational study. BMC Infectious Diseases, 2016, 16, 223.	2.9	25
54	Low levels of shortâ€and mediumâ€chain acylcarnitines in HIVâ€infected patients. European Journal of Clinical Investigation, 2016, 46, 408-417.	3.4	14

#	Article	IF	Citations
55	Circulating PCSK9 and Risk of MyocardialÂInfarction. JACC Basic To Translational Science, 2016, 1, 568-575.	4.1	21
56	Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway. Atherosclerosis, 2016, 244, 188-194.	0.8	18
57	The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review. Open Forum Infectious Diseases, 2016, 3, ofw048.	0.9	60
58	Hepatitis C reinfection after sustained virological response. Journal of Hepatology, 2016, 64, 1020-1026.	3.7	122
59	Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. European Heart Journal, 2016, 37, 2406-2413.	2.2	270
60	Early identification of sepsis in hospital inpatients by ward nurses increases 30-day survival. Critical Care, 2016, 20, 244.	5.8	60
61	Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystalâ€“Induced Inflammatory Responses by Reducing Complement Activation. Journal of Immunology, 2015, 195, 257-264.	0.8	27
62	Genetic variants in the DNA repair gene NEIL3 and the risk of myocardial infarction in a nested caseâ€“control study. The HUNT Study. DNA Repair, 2015, 28, 21-27.	2.8	20
63	Keap1 regulates inflammatory signaling in Mycobacterium avium -infected human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4272-80.	7.1	43
64	Epidemiology and outcome of Staphylococcus aureus bloodstream infection and sepsis in a Norwegian county 1996â€“2011: an observational study. BMC Infectious Diseases, 2015, 15, 116.	2.9	55
65	Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. Clinical and Translational Gastroenterology, 2015, 6, e95.	2.5	16
66	Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial Cells. PLoS ONE, 2015, 10, e0141710.	2.5	54
67	Lipocalin 2 Imparts Selective Pressure on Bacterial Growth in the Bladder and Is Elevated in Women with Urinary Tract Infection. Journal of Immunology, 2014, 193, 6081-6089.	0.8	54
68	Cytokine Network in Scrub Typhus: High Levels of Interleukin-8 Are Associated with Disease Severity and Mortality. PLoS Neglected Tropical Diseases, 2014, 8, e2648.	3.0	45
69	Mucosal Toll-like Receptor 3-dependent Synthesis of Complement Factor B and Systemic Complement Activation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1.	1.9	29
70	Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells. Cardiovascular Research, 2014, 102, 148-156.	3.8	37
71	Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release. Journal of Immunology, 2014, 192, 2837-2845.	0.8	236
72	Increased endothelial and macrophage markers are associated with disease severity and mortality in scrub typhus. Journal of Infection, 2014, 69, 462-469.	3.3	22

#	Article	IF	Citations
73	Enhanced Expression of CXCL10 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 265-274.	1.9	62
74	Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation. Innate Immunity, 2013, 19, 290-297.	2.4	22
75	Whole Genome Gene Expression Meta-Analysis of Inflammatory Bowel Disease Colon Mucosa Demonstrates Lack of Major Differences between Crohn's Disease and Ulcerative Colitis. PLoS ONE, 2013, 8, e56818.	2.5	111
76	Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses. PLoS ONE, 2013, 8, e69896.	2.5	21
77	The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure. PLoS ONE, 2012, 7, e33038.	2.5	33
78	A Complex Interaction between Rickettsia conorii and Dickkopf-1 â€“ Potential Role in Immune Evasion Mechanisms in Endothelial Cells. PLoS ONE, 2012, 7, e43638.	2.5	15
79	Effect of eptifibatide on platelet-mediated inflammation in acute coronary syndromes. International Journal of Cardiology, 2011, 151, 385-387.	1.7	4
80	No Inflammatory Response Related to Pulmonary Hemodynamics in Children with Systemic to Pulmonary Shunts. Congenital Heart Disease, 2011, 6, 338-346.	0.2	0
81	Treatment with the PPARÎ³ agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. European Journal of Endocrinology, 2010, 162, 267-273.	3.7	17
82	Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3039-3047.	3.6	89
83	Raised MCP-4 levels in symptomatic carotid atherosclerosis: an inflammatory link between platelet and monocyte activation. Cardiovascular Research, 2010, 86, 265-273.	3.8	35
84	Neutrophil Gelatinase-Associated Lipocalin. Chest, 2010, 138, 888-895.	0.8	89
85	The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis. Thrombosis and Haemostasis, 2009, 102, 704-710.	3.4	24
86	Elevated levels of activin A in clinical and experimental pulmonary hypertension. Journal of Applied Physiology, 2009, 106, 1356-1364.	2.5	55
87	IL-10 Enhances MD-2 and CD14 Expression in Monocytes and the Proteins Are Increased and Correlated in HIV-Infected Patients. Journal of Immunology, 2009, 182, 588-595.	0.8	27
88	Enhanced levels of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and response to highly active antiretroviral therapy. Aids, 2009, 23, 135-138.	2.2	19
89	C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. European Heart Journal, 2009, 30, 1180-1186.	2.2	143
90	Increased Production of CXCL16 in Experimental and Clinical Heart Failure. Circulation: Heart Failure, 2009, 2, 624-632.	3.9	38

#	Article	IF	Citations
91	Inflammatory Interaction Between LIGHT and Proteinase-Activated Receptor-2 in Endothelial Cells. Circulation Research, 2009, 104, 60-68.	4.5	28
92	Patients with Pulmonary Hypertension Related to Congenital Systemic-to-Pulmonary Shunts are Characterized by Inflammation Involving Endothelial Cell Activation and Platelet-mediated Inflammation. Congenital Heart Disease, 2009, 4, 153-159.	0.2	25
93	Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation. Clinical Immunology, 2009, 130, 151-161.	3.2	12
94	Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever. Journal of Infection, 2009, 58, 68-75.	3.3	34
95	The complex role of T-cell-based immunity in atherosclerosis. Current Atherosclerosis Reports, 2008, 10, 236-243.	4.8	24
96	Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. Journal of Molecular and Cellular Cardiology, 2008, 45, 261-269.	1.9	69
97	A Potential Role of the CXC Chemokine GROÎ± in Atherosclerosis and Plaque Destabilization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1005-1011.	2.4	54
98	High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovascular Research, 2008, 79, 195-203.	3.8	45
99	Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failureâ˜†. European Journal of Heart Failure, 2008, 10, 352-359.	7.1	30
100	Raised LIGHT Levels in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 202-207.	5.6	24
101	Chemokines and Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1909-1919.	2.4	161
102	Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis. Circulation, 2007, 115, 972-980.	1.6	428
103	Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 614-620.	2.4	134
104	Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. Atherosclerosis, 2007, 195, e142-e146.	0.8	35
105	Potential Mechanisms of Benefit with Thalidomide in Chronic Heart Failure. American Journal of Cardiovascular Drugs, 2007, 7, 127-134.	2.2	5
106	Microbubbles in the Pulmonary Artery Generated During Experimental Hepatic Radiofrequency Ablation Is Correlated with Increased Pulmonary Arterial Pressure. Journal of Vascular and Interventional Radiology, 2007, 18, 437-442.	0.5	7
107	T Cells in Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1459-1461.	2.8	9
108	Role of inflammation in the progression of heart failure. Current Cardiology Reports, 2007, 9, 236-241.	2.9	151

#	Article	IF	Citations
109	Chemokines in cardiovascular risk prediction. Thrombosis and Haemostasis, 2007, 97, 748-54.	3.4	22
110	Systemic markers of inflammation â€“ are they useful predictive tools in coronary artery disease?. Scandinavian Cardiovascular Journal, 2006, 40, 262-266.	1.2	3
111	Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. Journal of Hepatology, 2006, 44, 1167-1174.	3.7	493
112	The role of intravenous immunoglobulin in the treatment of chronic heart failure. International Journal of Cardiology, 2006, 112, 40-45.	1.7	29
113	Systemic inflammation in heart failure â€“ The whys and wherefores. Heart Failure Reviews, 2006, 11, 83-92.	3.9	252
114	Chemokines in Children With Heterozygous Familiar Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 200-205.	2.4	29
115	Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects. Stroke, 2006, 37, 1731-1736.	2.0	21
116	Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 857-863.	2.4	170
117	Increased Levels of Soluble CD40L in African Tick Bite Fever: Possible Involvement of TLRs in the Pathogenic Interaction betweenRickettsia africae, Endothelial Cells, and Platelets. Journal of Immunology, 2006, 177, 2699-2706.	0.8	47
118	Anti-inflammatory trials in chronic heart failure. Heart Failure Monitor, 2006, 5, 2-9.	0.7	9
119	Abnormal interleukin-7 function in common variable immunodeficiency. Blood, 2005, 105, 2887-2890.	1.4	54
120	Early anti-thrombotic and anti-inflammatory actions of statins and fibrates â€“ time for adjuvant therapy in acute coronary syndromes?. Thrombosis and Haemostasis, 2005, 94, 1-3.	3.4	34
121	Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2567-2572.	2.4	119
122	Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. Journal of Lipid Research, 2005, 46, 211-219.	4.2	78
123	Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. Expert Opinion on Pharmacotherapy, 2005, 6, 2169-2180.	1.8	3
124	Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Review of Cardiovascular Therapy, 2005, 3, 1111-1124.	1.5	12
125	Antiinflammatory Effects of Tetradecylthioacetic Acid Involve Both Peroxisome Proliferatorâ€“Activated Receptor Î±â€“Dependent and â€“Independent Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1364-1369.	2.4	27
126	Enhanced Plasma Levels of LIGHT in Unstable Angina. Circulation, 2005, 112, 2121-2129.	1.6	55

#	Article	IF	Citations
127	Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal, 2005, 26, 1101-1107.	2.2	71
128	Inflammatory and antiâ€inflammatory cytokines in chronic heart failure: Potential therapeutic implications. Annals of Medicine, 2005, 37, 74-85.	3.8	140
129	Agents targeting inflammation in heart failure. Expert Opinion on Investigational Drugs, 2005, 14, 557-566.	4.1	35
130	Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells â€“ potential role of prostaglandin E2. Thrombosis and Haemostasis, 2004, 92, 1358-1367.	3.4	20
131	Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors. Circulation, 2004, 109, 1966-1972.	1.6	142
132	Elevated Levels of Activin A in Heart Failure. Circulation, 2004, 109, 1379-1385.	1.6	150
133	Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. European Heart Journal, 2004, 25, 349-355.	2.2	151
134	Soluble CD40 Ligand in Pulmonary Arterial Hypertension. Circulation, 2004, 110, 999-1005.	1.6	99
135	Inflammation and chronic heart failureâ€“potential therapeutic role of intravenous immunoglobulin. Autoimmunity Reviews, 2004, 3, 221-227.	5.8	38
136	Platelet activation in heart transplant recipients. Clinical Transplantation, 2004, 18, 142-147.	1.6	20
137	Therapeutic Potential of Anticytokine Therapy in Congestive Heart Failure. American Journal of Cardiovascular Drugs, 2004, 4, 169-177.	2.2	12
138	Potential anti-inflammatory role of activin A in acute coronary syndromes. Journal of the American College of Cardiology, 2004, 44, 369-375.	2.8	53
139	Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy. Vascular Disease Prevention, 2004, 1, 17-31.	0.2	3
140	Immunomodulating Therapy: New Treatment Modality in Congestive Heart Failure. Congestive Heart Failure, 2003, 9, 64-69.	2.0	12
141	Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Journal of the American College of Cardiology, 2003, 41, 1460-1467.	2.8	99
142	Interleukin-7â€“Mediated Inflammation in Unstable Angina. Circulation, 2003, 107, 2670-2676.	1.6	105
143	8-Isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. Cardiovascular Research, 2003, 59, 945-954.	3.8	60
144	Stromal Cellâ€“Derived Factor-1Î± in Unstable Angina. Circulation, 2002, 106, 36-42.	1.6	139

#	Article	IF	Citations
145	Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovascular Research, 2002, 54, 175-182.	3.8	82
146	Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. Journal of the American College of Cardiology, 2001, 37, 485-491.	2.8	128
147	Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failureâ€"modulatory effect of intravenous immunoglobulin. Journal of the American College of Cardiology, 2001, 38, 187-193.	2.8	93
148	Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes. Basic Research in Cardiology, 2001, 96, 345-352.	5.9	42